Loading organizations...
§ Venture Capital · Richmond, VA, USA
Venture capital firm investing in growth-stage companies, providing capital and operational expertise for healthcare IT and services.
Co-founded by managing partners Tom Benedetti and Andrew Tichenor, Blue Heron Capital is a venture capital firm investing in growth-stage companies by providing capital and operational expertise. The firm primarily focuses on the healthcare IT and services sectors, leveraging a team with hands-on business management experience that has historically helped create over $2 billion in enterprise value. The organization manages multiple investment vehicles, including Blue Heron Capital Fund I, II, and III, generating returns through strategic exits. Its portfolio includes healthcare revenue cycle management company Verisma, which generated a 6.9x multiple on invested capital and a 40% internal rate of return. Alongside data analytics firm Stratasan, which yielded a 3.3x multiple and a 53% return, the firm features a leadership team including operating partner Jim Riley and executives like Scott Sanner with experience at McKesson and Millennia.
Key people at Blue Heron Capital.
Blue Heron Capital was founded in 2006 by Linda Gardner (Co-Founder).
Key people at Blue Heron Capital.
Blue Heron Capital is an early-stage growth equity investment firm specializing in healthcare and technology sectors. Their mission centers on partnering with innovative companies that leverage technology to improve healthcare delivery, reduce costs, and enhance patient experiences, particularly focusing on scalable B2B platforms with strong customer relationships and high switching costs. They combine financial capital with operational expertise through their OA Collaborative network to actively support portfolio companies’ growth and impact in the startup ecosystem[2][3][4].
Founded in 2006 and based in Richmond, VA, Blue Heron Capital was co-founded by Andrew Tichenor and Gordon Crenshaw, among others. Over time, the firm has evolved to focus on small-cap, high-growth healthcare and enterprise technology companies, typically investing in businesses with $3-$20 million in revenue that demonstrate capital efficiency, strong gross margins, and scalable business models. Their approach emphasizes minority growth equity investments in companies led by experienced management teams open to active investor involvement[2][4][5].
Blue Heron Capital rides the wave of digital transformation in healthcare, addressing critical trends such as cost containment, aging in place, and patient-centric care through technology innovation. The timing is favorable due to increasing demand for healthcare efficiency and technology adoption accelerated by demographic shifts and regulatory pressures. By investing in scalable B2B platforms with strong customer retention, Blue Heron influences the ecosystem by enabling companies that improve healthcare outcomes and operational efficiencies, thus contributing to the modernization of healthcare delivery systems[2][3].
Looking ahead, Blue Heron Capital is poised to deepen its impact by continuing to back innovative healthcare and enterprise technology companies that align with evolving market needs such as telehealth, digital patient engagement, and cost-effective care models. Trends like AI integration in healthcare and remote patient monitoring will likely shape their investment focus. Their combination of financial resources and operational expertise positions them to remain influential in driving growth and disruption in healthcare technology, reinforcing their role as a key growth equity partner in this dynamic sector[2][3].
In summary, Blue Heron Capital is a growth equity firm distinguished by its sector focus, active partnership model, and commitment to scaling technology-driven healthcare solutions that address pressing systemic challenges.
Blue Heron Capital was founded in 2006 by Linda Gardner (Co-Founder).
Blue Heron Capital has 23 tracked investments across 19 companies. The latest tracked deal is $12.0M Series A in Adpipe in September 2025.
